Section 4 of 6
Clinical evidence
249 evidence topics · 54 sources
Study summaries
LUGANO
Objective
Program objective: similar vision with dosing every 6 months and lower treatment burden
Role in the planned New Drug Application
Location and study date
Summary: sites and timeline
The ClinicalTrials.gov record (last updated 2026-09-03) lists 76 locations, all in the United States, which is consistent with the 2025 Form 10-K description of LUGANO as the United States trial and LUCIA as the United States and ex-United States trial; the first-participant announcement and a 2025 congress poster described both trials as global. The first participant was dosed in October 2024 (registry study start 2024-10-22), enrollment was completed on May 27, 2025, the registry reports actual primary completion on 2026-07-13, and topline results were announced on August 17, 2026. Estimated study completion (week 96) is 2027-08.
Registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2024-10-22” |
| Primary completion (actual) | “2026-07-13” |
| Study completion (estimated) | “2027-08” |
First participant dosed
Enrollment completion
Study design
Phase 3, randomized, double-masked, parallel-group, aflibercept-controlled design
Two identical non-inferiority trials with randomization on Day 1
Design elements agreed with FDA and EMA
Aflibercept loading, sham masking, and 24-month safety follow-up
Monthly monitoring with supplemental treatment in all arms
Independent Data Safety Monitoring Committee
Eligibility criteria
Key inclusion criteria
Geographic atrophy outside the center subfield was not excluded
Planned mix of treatment-naive and previously treated participants
Treatment
Registered arms
| Arm | Arm label | Intervention |
|---|---|---|
| Experimental | “EYP-1901 2686 µg” | “Intravitreal Injection” |
| Active comparator | “Aflibercept” | “Aflibercept (2.0 mg)” |
Dosing schedule: vorolanib insert every 6 months from week 8
Aflibercept loading doses before the first insert
Dosing visits reached during the trial
Supplemental aflibercept criteria: 2026 presentation
Supplemental aflibercept criteria: 2025 congress presentation
Study outcomes
Rationale for using mean change in best corrected visual acuity as the primary endpoint
Registered outcomes
| Outcome type | Measure | Time frame |
|---|---|---|
| Primary | “Average change in best corrected visual acuity (BCVA)” | “Weeks 52 and 56” |
| Secondary | “Rate of injection burden” | “Week 56” |
| Secondary | “Average change in best corrected visual acuity (BCVA)” | “Week 96” |
Primary endpoint and non-inferiority margin of 4.5 letters
Secondary endpoints
Precedent: 4.5-letter margin in the Archway port delivery system trial
“Primary end point was change in best-corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study letter (letters) score from baseline averaged over weeks 36 and 40 (noninferiority margin,-4.5 letters; equivalence margin, ±4.5 letters).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Precedent: 4.5-letter margin described as based on FDA guidance for another sustained-release tyrosine kinase inhibitor
Precedent: 4-letter margins in phase 3 trials versus aflibercept 2 mg every 8 weeks
“The primary endpoint was mean change in best-corrected visual acuity (BCVA) from baseline averaged over weeks 40, 44, and 48 (prespecified non-inferiority margin of four letters), in the intention-to-treat population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The least squares mean differences between aflibercept 8q12 versus 2q8 and 8q16 versus 2q8, respectively, were -0·97 (95% CI -2·87 to 0·92) and -1·14 (-2·97 to 0·69) letters (non-inferiority margin at 4 letters).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FDA framework for selecting a non-inferiority margin
Archway: justification for the 4.5-letter noninferiority and equivalence margins
“The noninferiority and equivalence margins were chosen to reduce the possibility of a positive trial where the lower confidence level was too close to the current consensus definition of a clinically meaningful difference of 5 letters.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
TENAYA and LUCERNE: sample size, endpoint averaging, and choice of the every-8-week aflibercept comparator
“Sample size of approximately 320 patients in each treatment group (ie, N=640 per trial) was estimated to provide more than 90% power to test the primary comparison of non-inferiority of faricimab (up to every 16 weeks) to aflibercept (every 8 weeks) for each trial, using a non-inferiority margin of four ETDRS letters” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Primary efficacy outcome was averaged over three timepoints to limit impact of measurement variability and account for differences in time from last dose received by patients across treatment groups on different dosing intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Lower bounds of the two-sided 95% CIs for difference in adjusted means of the two treatments were well within the non-inferiority margin of four letters, establishing non-inferiority of faricimab to aflibercept” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fixed 8-week aflibercept dosing, which was used in the pivotal phase 3 trials of aflibercept, was therefore the most appropriate regimen against which to evaluate noninferiority of a new treatment, especially considering the potential for extended dosing with faricimab at up to 16-week repeating intervals.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Source field | Value |
|---|---|
| Registry enrollment (estimated) | “400” |
Participants analyzed
| Analysis | DURAVYU 2.7 mg | Aflibercept 2 mg |
|---|---|---|
| Baseline characteristics and efficacy | “DURAVYU 2.7mg (n=211)” | “Aflibercept 2mg q8W (n=216)” |
| Ocular adverse events | “DURAVYU 2.7mg (N=211)” | “Aflibercept 2mg (N=221)” |
Sample size calculation and power
No evidence found.
Description of analysis sets
Summary: analysis methods and populations reported
The topline presentations report the primary endpoint as a mixed model for repeated measures (MMRM) estimate of change from baseline blended across weeks 52 and 56, tested against a margin of -4.5 letters. Efficacy tables use 211 participants in the vorolanib insert arm and 216 in the aflibercept arm (427 of 432 randomized participants, 98.8%); the ocular adverse event table uses 211 and 221 participants (432 of 432). The definition of the efficacy population, the method for handling missing data, the confidence interval for the full-dataset treatment difference, and any multiplicity procedure for secondary endpoints were not reported. All p-values for the ad hoc analysis, the prespecified supplement-free subgroup analysis, and the treatment burden endpoint were labeled nominal. The September 2026 presentation added a median regression analysis and a randomization simulation labeled as new analyses. All results were labeled preliminary and pending final analysis.
Ad hoc analysis excluding the asymmetric cohort
Multiplicity control and handling of missing data
No evidence found.
Results
Participant disposition
Summary: disposition through week 56
Of 432 randomized participants, 211 in the vorolanib insert arm and 216 in the aflibercept arm were included in efficacy analyses, and 211 and 221 in the ocular adverse event table. Discontinuation through week 56 was 6% in each arm, and none was attributed to the vorolanib insert. Reading center assessments at week 56 included 193 and 197 participants for subretinal fibrosis and 168 per arm for fundus autofluorescence. A full CONSORT flow was not reported.
Participants with reading center assessments at week 56
Baseline characteristics
Demographics, treatment history, and ocular characteristics
| Characteristic | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg q8W (n=216) |
|---|---|---|
| Age, years, mean (SD) | “77.5 (7.52)” | “77.0 (7.61)” |
| Age 65 years or older, n (%) | “202 (95.7)” | “205 (94.9)” |
| Female, n (%) | “136 (64.5)” | “141 (65.3)” |
| Treatment naive, n (%) | “159 (75.4)” | “164 (75.9)” |
| Previously treated, n (%) | “52 (24.6)” | “52 (24.1)” |
| Annualized number of anti-VEGF injections for previously treated, mean (SD) | “7.35 (2.21)” | “7.39 (2.01)” |
| BCVA, ETDRS letters, mean (SD) | “65.8 (8.95)” | “64.3 (10.35)” |
| Better than 20/40 Snellen equivalent, n (%) | “82 (38.9)” | “79 (36.6)” |
| 20/40 Snellen equivalent or worse, n (%) | “129 (61.1)” | “137 (63.4)” |
| Central subfield thickness, µm, mean (SD) | “319.83 (71.429)” | “326.01 (71.906)” |
| Total CNV area by fluorescein angiography, mm2, mean (SD) | “5.69 (4.44)” | “4.60 (3.86)” |
| Medical history of dry AMD in study eye | “24.6%” | “21.7%” |
| Medical history of glaucoma in study eye | “11.4%” | “5.9%” |
Geographic atrophy at baseline
Efficacy results
Summary: primary and key secondary efficacy results
LUGANO did not meet its primary endpoint of non-inferiority (margin -4.5 letters) in mean BCVA change from baseline to weeks 52 and 56 in the full dataset; the numeric treatment difference and confidence interval for the full dataset were not reported in text. In the full dataset, the vorolanib insert arm showed a mean BCVA gain from baseline. Nine of 211 participants (4.3%) in the vorolanib insert arm and none of 216 in the aflibercept arm lost 15 or more letters from causes the company attributed to conditions other than wet AMD (geographic atrophy, 6; glaucoma, 2; retinal detachment, 1). In an ad hoc analysis excluding these 9 participants, least squares mean BCVA change was +3.5 letters with the vorolanib insert and +5.9 letters with aflibercept (difference -2.4 letters; nominal p=0.0096). In the September 2026 presentation, a median regression analysis of all participants with week 52 or week 56 BCVA gave a median difference of -1.4 letters, and random reassignment of the 16 participants with any loss of 15 or more letters gave modeled differences of -1.3 to -2.0 letters. The presentation chart shows 15-letter or greater loss in 7.5% of the vorolanib insert arm (4.5% attributed to non-wet AMD causes) and 0.5% of the aflibercept arm.
Mean injections after loading through week 56 were 3.1 with the vorolanib insert and 5.3 with aflibercept, a 42% reduction (nominal p<0.0001), with an average of 1.1 supplemental injections annualized in the vorolanib insert arm. Supplement-free rates in the vorolanib insert arm were 76% through week 32 and 54% through week 56. In the supplement-free subgroup (113 participants receiving the vorolanib insert, compared with 192 aflibercept participants shown in the chart legend), BCVA change was +4.7 versus +6.4 letters (difference -1.8; nominal p=0.0035). Mean central subfield thickness change at week 56 was -72 µm versus -76 µm (difference +4 µm).
Primary endpoint: full dataset
Primary endpoint: full-dataset treatment difference and confidence interval
No evidence found.
Asymmetric cohort with vision loss attributed to causes other than wet AMD
Ad hoc analysis excluding the asymmetric cohort
| Measure | Value |
|---|---|
| Least squares mean BCVA change, DURAVYU 2.7 mg, excluding asymmetric cohort | “DURAVYU arm gained +3.5 letters” |
| Least squares mean BCVA change, aflibercept 2 mg | “+5.9” |
| Mean change in BCVA versus aflibercept | “-2.4” |
| p-value | “(nominal non-inferiority p=0.0096)” |
Sensitivity analyses reported in September 2026
Loss of 15 or more letters in the aflibercept arm compared with prior trials
| Trial | Aflibercept 2 mg every 8 weeks, N | Timepoint | Participants with loss of 15 or more letters |
|---|---|---|---|
| VIEW 1 | “301” | “Week 52” | “4.9%a” |
| VIEW 2 | “306” | “Week 52” | “4.4%a” |
| HAWK | “360” | “Week 48” | “5.5%b” |
| HARRIER | “369” | “Week 48” | “4.8%b” |
| TENAYA | “300” | “Week 40-48, avg” | “5.9%c” |
| LUCERNE | “291” | “Week 40-48, avg” | “2.7%d” |
| PULSAR | “335” | “Week 48” | “3.3%e” |
| DAVIO 2 | “54” | “Week 56” | “7.7%f” |
| LUGANO | “216” | “Week 52/56, avg” | “0.5%f” |
Supplement-free rates in the vorolanib insert arm
| Measure | Up to week 32 | Up to week 56 |
|---|---|---|
| Supplement-free patients | “76% of DURAVYU patients were supplement-free up to Week 32” | “54% of DURAVYU patients were supplement-free up to Week 56” |
| Zero or one supplement | “94 % of DURAVYU patients received zero or one supplement up to Week 32” | “79% of DURAVYU patients received zero or one supplement up to Week 56” |
Supplement-free subgroup: visual acuity and central subfield thickness
Response to supplemental aflibercept
Anatomic outcomes: central subfield thickness
Anatomic outcomes: subretinal fibrosis
| Measure | DURAVYU 2.7 mg | Aflibercept 2 mg |
|---|---|---|
| Subretinal fibrosis present, baseline | “2.8% (6 of 211)” | “1.4% (3 of 216)” |
| Subretinal fibrosis present, week 56 | “4.1% (8 of 193)” | “4.1% (8 of 197)” |
| Progression of fibrosis from baseline | “+ 46%” | “+ 193%” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Summary: ocular safety through week 56
Through week 56, the vorolanib insert arm (211 participants) and aflibercept arm (221 participants) had cataract in 4.3% and 5.4%, increased intraocular pressure in 3.8% and 3.2%, intraocular inflammation in 0.5% and 0.5%, and retinal detachment in 0.5% and 0.5% of participants. Ocular adverse events reported more often with the vorolanib insert included conjunctival hemorrhage (11.4% versus 5.0%), vitreous floaters (9.0% versus 3.6%), neovascular AMD (7.1% versus 1.4%), retinal hemorrhage (4.7% versus 1.8%), retinal edema (2.8% versus 0.9%), and visual impairment (2.4% versus 0.0%). No insert migration into the anterior chamber, anterior chamber opacities, free-floating particles, retinal vasculitis, or severe intraocular inflammation were reported. Serious adverse events, systemic adverse events, and endophthalmitis counts were not reported numerically; endophthalmitis was reported at less than 1% in both arms.
Adverse events of particular interest and events not observed
Ocular adverse events in the study eye occurring in 2% or more of participants through week 56
| Adverse event | DURAVYU 2.7 mg (n=211) | Aflibercept 2 mg (n=221) |
|---|---|---|
| Conjunctival haemorrhage | “11.4%” | “5.0%” |
| Vitreous floaters | “9.0%” | “3.6%” |
| Neovascular age-related macular degeneration | “7.1%” | “1.4%” |
| Retinal haemorrhage | “4.7%” | “1.8%” |
| Vitreous detachment | “4.7%” | “4.1%” |
| Cataract | “4.3%” | “5.4%” |
| Dry eye | “4.3%” | “6.3%” |
| Posterior capsule opacification | “4.3%” | “2.3%” |
| Intraocular pressure increased | “3.8%” | “3.2%” |
| Visual acuity reduced | “3.8%” | “5.4%” |
| Retinal oedema | “2.8%” | “0.9%” |
| Visual impairment | “2.4%” | “0.0%” |
| Dry age-related macular degeneration | “2.4%” | “3.2%” |
| Eye pain | “2.4%” | “0.9%” |
| Subretinal fluid | “2.4%” | “1.4%” |
Selected ocular adverse events including geographic atrophy
| Adverse event | DURAVYU 2.7 mg (N=211) | Aflibercept 2 mg (N=221) |
|---|---|---|
| Intraocular inflammation (IOI) | “0.5%” | “0.5%” |
| Geographic atrophy (lower-level term) | “2.4%” | “2.7%” |
| Retinal detachment | “0.5%” | “0.5%” |
| Vision loss in participant with retinal detachment | “-40 letters” | “+1 letter” |
Geographic atrophy onset and growth by reading center
Serious and systemic adverse events
No evidence found.
Study limitations
Summary
- The primary endpoint was not met in the full dataset. Non-inferiority was shown only in an ad hoc analysis that removed 9 of 211 participants (4.3%) in the vorolanib insert arm whose loss of 15 or more letters was attributed by retina specialists to causes other than wet AMD; the same attribution identified 0 of 216 aflibercept participants, and p-values for this and all secondary analyses are nominal.
- The full-dataset treatment difference and its confidence interval, the multiplicity procedure, missing data handling, and the efficacy population definition have not been reported; results are topline, labeled preliminary and pending final analysis, and were not peer reviewed as of September 2026.
- The aflibercept arm had a 0.5% rate of 15-letter or greater loss, lower than the 2.7% to 7.7% rates the sponsor cited from earlier trials, while the vorolanib insert arm had 7.5%. The sponsor attributes the imbalance to chance and to baseline differences; this cannot be confirmed from one trial. LUCIA, the identical second trial, also did not meet the primary endpoint (difference -3.7 letters), and its rate of 15-letter or greater loss has not been reported in text.
- Baseline imbalances favored the aflibercept arm on some risk factors for vision loss unrelated to neovascular activity: glaucoma history 11.4% versus 5.9%, total CNV area 5.69 versus 4.60 mm2, and geographic atrophy located closer to the fovea (825 versus 1009 µm); eligibility excluded only center-subfield atrophy.
- Vorolanib insert participants received three aflibercept loading doses before the first insert, supplemental aflibercept was available in both arms, and the supplement criteria wording differs between 2025 and 2026 company presentations; the efficacy therefore reflects a regimen of aflibercept loading plus insert plus supplemental aflibercept, not insert monotherapy.
- The comparator was fixed aflibercept 2 mg every 8 weeks, not treat-and-extend dosing, faricimab, or aflibercept 8 mg, and all 76 registry sites were in the United States.
- Efficacy is reported to week 56 only; year 2 was designed as a safety-only continuation, and EyePoint stated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year, so year 2 safety follow-up will be incomplete; no patient-reported outcome or quality-of-life data have been reported, and systemic and serious adverse event data are not yet public.
- Treatment burden was compared with a fixed aflibercept schedule that allows a maximum 60% reduction, so the 42% reduction measures scheduled injection frequency rather than burden relative to extended-interval regimens.
LUCIA
Objective
Program objective: similar vision with dosing every 6 months and lower treatment burden
Role in the planned New Drug Application after LUGANO
Location and study date
Summary: sites and timeline
The ClinicalTrials.gov record (last updated 2026-09-03) lists 113 locations: 78 in the United States, 7 in Israel, 7 in Poland, 6 in India, 5 in Brazil, 4 in Hungary, 3 in Czechia, and 1 each in Germany, Slovakia, and the United Kingdom. The 2025 enrollment completion announcement also names participation in Australia, which the registry does not list. The first participant was dosed in December 2024 (registry study start 2024-11-27), enrollment was completed on July 29, 2025, the registry estimated primary completion for 2026-10 and study completion for 2027-10, and topline results were announced on October 19, 2026. The same day, EyePoint announced that it would conclude the trial early, without full completion of its second year.
Registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2024-11-27” |
| Primary completion (estimated) | “2026-10” |
| Study completion (estimated) | “2027-10” |
Countries
Topline results announced October 19, 2026, and early conclusion of the trial
Study design
Phase 3, randomized, double-masked, parallel-group, aflibercept-controlled design
Identical design to LUGANO
Aflibercept loading, sham masking, and 24-month safety follow-up
“Sham injections used for masking” (opens the source at this quote in a new tab)
“On-label aflibercept control group” (opens the source at this quote in a new tab)
Eligibility criteria
Key inclusion criteria
Planned mix of treatment-naive and previously treated participants
Treatment
Registered arms
| Arm | Arm label | Intervention |
|---|---|---|
| Experimental | “EYP-1901 2686 µg” | “Intravitreal Injection” |
| Active comparator | “Aflibercept” | “Aflibercept (2.0 mg)” |
Dosing schedule: vorolanib insert every 6 months from month 2
Supplemental aflibercept criteria
Dosing visits reached during the trial
Study outcomes
Rationale for using mean change in best corrected visual acuity as the primary endpoint
Summary: rationale for the endpoint and margin
LUCIA uses the same primary endpoint and -4.5-letter margin as LUGANO. The sponsor cites non-inferiority margin precedent from recent FDA approvals in neovascular AMD, and published phase 3 trials in neovascular AMD used margins of 4.5 letters (Archway, port delivery system with ranibizumab) or 4 letters (TENAYA and LUCERNE, faricimab; PULSAR, aflibercept 8 mg).
Registered outcomes
| Outcome type | Measure | Time frame |
|---|---|---|
| Primary | “Average change in best corrected visual acuity (BCVA)” | “Weeks 52 and 56” |
| Secondary | “Rate of injection burden” | “Week 56” |
| Secondary | “Average change in best corrected visual acuity (BCVA)” | “Week 96” |
Primary endpoint and non-inferiority margin of 4.5 letters
Secondary endpoints
PULSAR: sample size assumptions and noninferiority test results at the four-letter margin
“A SD of 13·6 letters was assumed for each group. Assuming a dropout rate of 10% by week 48, approximately 320 patients were planned for each group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The aflibercept 8q12 and 8q16 groups met the primary efficacy endpoint and showed non-inferior BCVA gains compared with the aflibercept 2q8 group, based on a non-inferiority margin of 4 letters” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The estimated difference in least square mean changes from baseline to week 48 in BCVA for aflibercept 8q12 versus 2q8 was –0·97 (95% CI –2·87 to 0·92; noninferiority test at four-letter margin: p=0∙0009) and for aflibercept 8q16 versus 2q8 was –1·14 (–2·97 to 0·69; p=0∙0011).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
| Source field | Value |
|---|---|
| Registry enrollment (estimated) | “400” |
Enrolled and randomized participants
Participants analyzed
| Analysis | DURAVYU 2.7 mg | Aflibercept 2 mg |
|---|---|---|
| Baseline characteristics table | “DURAVYU 2.7mg (n=232)” | “Aflibercept 2mg q8W (n=238)” |
| Ocular adverse event table | “DURAVYU 2.7mg (n=232)” | “Aflibercept 2mg (n=243)” |
Description of analysis sets
Analysis plan informed by LUGANO results
Analysis populations, model, and multiplicity control
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline characteristics by arm
| Characteristic | DURAVYU 2.7 mg (n=232) | Aflibercept 2 mg every 8 weeks (n=238) |
|---|---|---|
| Age (years), mean (SD) | “76.8 (8.4)” | “77.2 (8.5)” |
| Female, n (%) | “144 (62.1)” | “129 (54.2)” |
| Treatment naive, n (%) | “176 (75.9)” | “179 (75.2)” |
| Previously treated, n (%) | “56 (24.1)” | “59 (24.8)” |
| BCVA (ETDRS letters), mean (SD) | “65.0 (10.0)” | “64.5 (10.3)” |
| Central subfield thickness (µm), mean (SD) | “314.8 (76.5)” | “318.3 (82.3)” |
Efficacy results
Summary: primary and key secondary efficacy results
LUCIA did not meet its primary endpoint of non-inferiority (margin -4.5 letters) in mean BCVA change from baseline to blended weeks 52 and 56. Least squares mean BCVA change was +2.5 letters with the vorolanib insert and +6.1 letters with aflibercept 2 mg every 8 weeks (difference -3.7 letters), with the confidence interval outside the 4.5-letter margin; the confidence interval itself was not reported in text. Mean injections after loading through week 56 were 3.3 with the insert and 5.3 with aflibercept, a 38% reduction (nominal p<0.0001). Supplement-free rates in the insert arm were 70% up to week 32 and 52% up to week 56, and 94% and 71% of insert participants received zero or one supplemental injection over the same periods. Mean central subfield thickness change through week 56 was -66 µm with the insert and -82 µm with aflibercept (difference +16 µm; nominal p=0.002). All results are labeled preliminary and pending final analysis.
Primary endpoint: mean change in BCVA
| Measure | Quoted result |
|---|---|
| Aflibercept 2 mg every 8 weeks | “+6.1 letters” |
| DURAVYU 2.7 mg every 24 weeks | “+2.5 letters” |
| Difference | “Difference -3.7 letters” |
| Non-inferiority | “DURAVYU did not meet non-inferiority (CI outside 4.5 letters)” |
| Data status | “Preliminary data – pending final analysis” |
Treatment burden and supplement-free rates
| Measure | Quoted result |
|---|---|
| Total injections after loading doses, aflibercept and DURAVYU | “5.3 3.3” |
| Treatment burden reduction | “38% Fewer Injections” |
| Supplement-free patients, up to week 32 and week 56 | “Supplement-Free Patients 70% 52%” |
| Patients with 0 or 1 supplement, up to week 32 and week 56 | “Patients with 0 or 1 Supplement 94% 71%” |
Central subfield thickness
| Measure | Quoted result |
|---|---|
| Aflibercept 2 mg every 8 weeks | “-82 µm” |
| DURAVYU 2.7 mg every 24 weeks | “-66 µm” |
| Difference | “Difference +16 µm” |
| Nominal p-value | “Nominal p=0.002” |
Sponsor expectation of regression to the mean in 15-letter losses
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Interim masked safety across LUGANO and LUCIA
Unmasked LUCIA safety results
Ocular adverse events in the study eye occurring in 2% or more of participants through week 56
Study limitations
Summary
- LUCIA results are topline sponsor reports from October 19, 2026, labeled preliminary and pending final analysis; the confidence interval for the primary endpoint difference, serious and systemic adverse events, and the rate of 15-letter or greater vision loss have not been reported in text.
- The baseline characteristics table includes 232 insert and 238 aflibercept participants and the adverse event table 232 and 243 (475 randomized); the analysis population for the primary endpoint has not been reported.
- EyePoint announced on October 19, 2026, that it would conclude both phase 3 wet AMD trials early, without full completion of the second year of each trial, and restated on November 12, 2026, that it will conclude the wet AMD program before completion of the full second year, so planned year 2 safety follow-up will be incomplete.
- The sponsor states that learnings from LUGANO were included in the LUCIA analysis plan before LUCIA topline results; the content of these changes has not been disclosed, and changes made after results of an identical trial are known may affect how the LUCIA primary analysis is interpreted.
- The design is identical to LUGANO, so the same design limitations apply: three aflibercept loading doses before the first insert, supplemental aflibercept in both arms, a fixed aflibercept 2 mg every 8 weeks comparator, a -4.5-letter margin, efficacy assessed to week 56 with safety-only follow-up in year 2, and exclusion of only center-subfield atrophy.
- Enrollment (475 participants) exceeded the registry estimate of 400, and the registry lists 113 sites in 10 countries, 78 (69.0%) of them in the United States; the registry does not list Australia, which the sponsor named as a participating country.
- Neither LUGANO nor LUCIA met the prespecified primary endpoint, so no phase 3 trial has shown non-inferiority in BCVA to aflibercept 2 mg every 8 weeks in its full dataset.
DAVIO 2
Objective
Post hoc analysis objective: supplemental injection patterns
Location and study date
Registry dates
| Field | Quoted record |
|---|---|
| First submitted | “2022-05-09” |
| Results first posted | “2025-10-02” |
Study design
Registered design
| Field | Quoted record |
|---|---|
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Primary purpose | “Treatment” |
| Study periods | “This study consists of a screening period (up to 14 days) and treatment period (56 weeks).” |
Prespecified supplemental aflibercept criteria
Definition of supplemental therapy
Design changes between the 2022 plan and the conducted trial
Eligibility criteria
Key inclusion criteria
Key ocular exclusion criteria
Key systemic exclusion criteria
Treatment
Treatment arms
Relation of the phase 2 doses to the phase 3 dose
Study outcomes
Rationale for using Best-Corrected visual acuity as the primary endpoint
Post hoc BCVA time-in-range analysis
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants
Description of analysis sets
Full analysis and safety sets as registered
Participants excluded from the full analysis set
Primary analysis model
Handling of missing visit data in supplement-free analyses
Median time to first supplemental injection: censoring
Results
Participant disposition
Disposition through week 56
| Milestone or reason | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Started | “54” | “53” | “54” |
| Completed | “52” | “47” | “52” |
| Not completed | “2” | “6” | “2” |
| Adverse event: ocular, study eye | “0” | “1” | “0” |
| Adverse event: non-ocular | “0” | “1” | “0” |
| Lost to follow-up | “1” | “0” | “0” |
| Protocol deviation | “0” | “2” | “0” |
| Withdrawal by subject | “1” | “0” | “1” |
| Death | “0” | “2” | “0” |
| Discontinued study without receiving study drug | “0” | “0” | “1” |
Discontinuations up to week 32
Baseline characteristics
Demographics: full analysis set
| Characteristic | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
|---|---|---|---|
| Age, mean (SD), years | “75.9(7.59)” | “76.4(6.66)” | “75.4(7.19)” |
| Female | “29” | “32” | “35” |
| White | “53” | “50” | “51” |
Ocular characteristics and prior treatment: full analysis set
| Characteristic | EYP-1901 2 mg, 50 participants | EYP-1901 3 mg, 52 participants | Aflibercept every 8 weeks, 54 participants |
|---|---|---|---|
| BCVA, mean (range), letters | “73.9 (52–84)” | “74.9 (46–85)” | “73.4 (41–85)” |
| CST, mean (range), µm | “264.5 (192–400)” | “262.9 (186–345)” | “265.7 (178–348)” |
| Duration of neovascular AMD, mean (range), years | “2.0 (0.1–7.9)” | “2.2 (0.2–10.8)” | “2.2 (0.2–20.2)” |
| Anti-VEGF injections per 12 months, normalized mean (range) | “9.8 (2–13)” | “10.0 (2–13)” | “9.5 (2–13)” |
Efficacy results
Summary: DAVIO 2 efficacy through week 56
DAVIO 2 randomized 161 participants; the full analysis set included 156 (54 aflibercept 2 mg every 8 weeks, 50 EYP-1901 2060 mcg, 52 EYP-1901 3090 mcg). For the primary endpoint (BCVA change averaged over weeks 28 and 32), the registry reports least-squares mean changes of 1.17, 1.05, and 0.87 letters, with differences versus aflibercept of -0.12 letters (95% CI, -2.48 to 2.24) for 2060 mcg and -0.31 letters (95% CI, -2.63 to 2.02) for 3090 mcg; both lower confidence limits were above the -4.5-letter noninferiority margin. EyePoint's topline release reported differences of -0.3 and -0.4 letters. At week 56, mean BCVA change was 1.1 letters with aflibercept, 0.3 letters with 2060 mcg, and -1.9 letters with 3090 mcg. Up to week 32, 62.5% and 63.5% of EYP-1901 participants received no supplemental aflibercept, compared with 94.3% of aflibercept participants; at week 56, the proportions were 42.6%, 46.2%, and 82.7%. The normalized number of aflibercept injections through week 56 was 3.45 and 3.36 in the EYP-1901 arms and 6.33 in the aflibercept arm.
Primary endpoint: BCVA change averaged over weeks 28 and 32
| Statistic | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Least-squares mean change, letters | “1.17” | “1.05” | “0.87” |
| Least-squares mean difference vs aflibercept, letters | Not applicable | “-0.12” | “-0.31” |
| 95% CI lower limit | Not applicable | “-2.48” | “-2.63” |
| 95% CI upper limit | Not applicable | “2.24” | “2.02” |
| P value | Not applicable | “0.919” | “0.795” |
Primary endpoint: company-reported topline result
Categorical BCVA change at weeks 32 and 56
| Category, percentage of participants | Aflibercept 2 mg, 53 participants | EYP-1901 2060 mcg, 48 participants | EYP-1901 3090 mcg, 52 participants |
|---|---|---|---|
| Week 32, gain of 5 or more letters | “34.0” | “25.0” | “21.2” |
| Week 32, loss of 5 or more letters | “13.2” | “20.8” | “11.5” |
| Week 32, loss of 15 or more letters | “1.9” | “0” | “1.9” |
| Week 56, gain of 5 or more letters | “32.7” | “23.4” | “15.4” |
| Week 56, loss of 5 or more letters | “23.1” | “23.4” | “32.7” |
| Week 56, loss of 10 or more letters | “11.5” | “10.6” | “13.5” |
| Week 56, loss of 15 or more letters | “7.7” | “4.3” | “3.8” |
Categorical BCVA change at month 7/8: company-reported
Median time to first supplemental aflibercept injection after week 8
| Statistic | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
|---|---|---|
| Median, weeks | “37.00” | “40.79” |
| 95% CI | “(20.14 to NA)” | “(20.00 to NA)” |
Normalized aflibercept injections, including loading doses
| Visit, mean (SD) | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
|---|---|---|---|
| Week 32 | “3.23(0.357)” | “2.06(0.583)” | “2.13(0.747)” |
| Week 56 | “6.33(0.754)” | “3.45(1.738)” | “3.36(1.854)” |
Treatment burden compared with the pre-trial period
Reasons for supplemental injections up to week 32
“24% (12/50) of EYP-1901 2 mg patients” (opens the source at this quote in a new tab)
“31% (16/52) of EYP-1901 3 mg patients” (opens the source at this quote in a new tab)
Anatomic outcomes at weeks 32 and 56
| Measure | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| CST, baseline mean, µm | “265.7” | “264.5” | “262.9” |
| CST, week 32 mean change, µm | “5.4” | “17.8” | “10.6” |
| CST, week 56 mean change, µm | “8.1” | “12.2” | “16.7” |
| No detectable intraretinal fluid in the central subfield, week 32, % | “62.3” | “52.1” | “51.9” |
| No detectable intraretinal fluid in the central subfield, week 56, % | “59.6” | “59.6” | “51.9” |
Subgroup: eyes without supplemental treatment through month 8
| Arm | Supplement-free subgroup size |
|---|---|
| EYP-1901 3 mg | “EYP-1901 3 mg, n=33” |
| EYP-1901 2 mg | “EYP-1901 2 mg, n=30” |
| Aflibercept every 8 weeks | “Aflibercept q8W, n=46” |
Subgroup: supplement-free eyes, BCVA difference versus aflibercept at month 7/8
| Arm | Mean change in BCVA vs aflibercept |
|---|---|
| EYP-1901 2 mg | “DURAVYU 2mg +0.6” |
| EYP-1901 3 mg | “DURAVYU 3mg +0.1” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Participants with treatment-emergent adverse events through week 56
| Category | Aflibercept 2 mg, 54 participants | EYP-1901 2060 mcg, 50 participants | EYP-1901 3090 mcg, 52 participants |
|---|---|---|---|
| Any TEAE, study eye | “30” | “30” | “30” |
| Any TEAE, fellow eye | “21” | “11” | “20” |
| Any TEAE, systemic | “40” | “28” | “39” |
| Serious TEAE, study eye | “2/54 (3.70%)” | “0/50 (0.00%)” | “4/52 (7.69%)” |
| Serious TEAE, fellow eye | “1/54 (1.85%)” | “0/50 (0.00%)” | “0/52 (0.00%)” |
| Serious TEAE, systemic | “6/54 (11.11%)” | “6/50 (12.00%)” | “9/52 (17.31%)” |
| All-cause mortality, systemic | “0/54 (0.00%)” | “2/50 (4.00%)” | “0/52 (0.00%)” |
Study eye serious adverse events: endophthalmitis
| Event, study eye | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Endophthalmitis | “2/54 (3.70%)” | “0/50 (0.00%)” | “3/52 (5.77%)” |
| Non-infectious endophthalmitis | “0/54 (0.00%)” | “0/50 (0.00%)” | “1/52 (1.92%)” |
Study eye serious adverse events: investigator-reported timing (November 2023 data cut)
Selected non-serious adverse events
| Event | Aflibercept 2 mg | EYP-1901 2060 mcg | EYP-1901 3090 mcg |
|---|---|---|---|
| Visual acuity reduced, study eye | “3/54 (5.56%)” | “1/50 (2.00%)” | “8/52 (15.38%)” |
| Vitreous floaters, study eye | “1/54 (1.85%)” | “2/50 (4.00%)” | “6/52 (11.54%)” |
| Hypertension, systemic | “4/54 (7.41%)” | “2/50 (4.00%)” | “7/52 (13.46%)” |
Company-reported safety findings through end of study
Study limitations
Summary
DAVIO 2 was a phase 2 trial with 50 to 54 participants per arm in the full analysis set, conducted at 39 sites in the United States, with 154 of 156 participants (98.7%) reported as White. Eligibility required a documented anatomic response to prior anti-VEGF therapy, at least 2 anti-VEGF injections in the prior 6 months, and CST of 350 µm or less, so treatment-naive eyes and eyes with greater baseline exudation were not studied. All arms received aflibercept loading at day 1, week 4, and week 8, including an aflibercept injection given with the EYP-1901 insert at week 8. The tested doses (2060 mcg and 3090 mcg, single administration) differ from the 2.7-mg dose given every 6 months in phase 3. The primary endpoint was measured 20 to 24 weeks after insert administration; the week 56 BCVA, supplement-free, and injection-count outcomes are descriptive secondary outcomes without reported hypothesis tests. Company presentations defined the full analysis set as participants who received both day 1 and week 8 treatments, whereas the registry describes it as participants who received at least 1 dose, and company-reported differences for the primary endpoint (-0.3 and -0.4 letters) differ from the registry least-squares differences (-0.12 and -0.31 letters). Several subgroup and time-in-range analyses were post hoc. No peer-reviewed full publication of DAVIO 2 was identified; most results come from sponsor press releases, sponsor-funded congress presentations, and the registry record.
DAVIO
Objective
Primary and secondary objectives
“The primary objective of this study was to evaluate the safety and determine the maximum tolerated dose of the EYP-1901 intravitreal insert for the treatment of patients with wAMD, based on ocular treatment-emergent adverse events (TEAEs) in the study and fellow eye, as well as nonocular adverse events (AEs), including clinical laboratory findings.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Posthoc exploratory analyses were conducted to evaluate reduction in treatment burden and supplemental injection-free rate.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Sites and study period
“The study was a phase I, multicenter (11 sites in the US), prospective, open-label, dose escalation trial.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study was conducted from January 2021 to May 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2021-01-20” |
| Primary completion (actual) | “2022-05-11” |
Study design
Dose-escalation design
“All patients in the study received EYP-1901, and both patients and investigators were not masked.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“According to the study protocol, 3 successive dose cohorts were planned to be enrolled in the dose-escalation phase, and depending on toxicity, up to 26 patients could have been enrolled during this phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study duration was 48 weeks, and the study consisted of a patient screening phase and a sequential dose-escalation phase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Criteria for additional anti-VEGF injections
“Administration of additional Food and Drug Administration-approved anti-VEGF treatment for wAMD (e.g., ranibizumab or aflibercept; not brolucizumab) or off-label bevacizumab was allowed at the investigator's discretion if a patient had a new or worsening vision-threatening hemorrhage since day 0 due to wAMD, an increase in CST of >75 μm from day 0, or a loss of ≥10 ETDRS letters from day 0 with intraretinal or subretinal fluid and/or hemorrhage judged to be the cause of BCVA loss.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria
“They must have received ≥3 prior injections with the same anti-VEGF agent (including bevacizumab, ranibizumab, or aflibercept) in the 6 months prior to the screening visit, in the study eye.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients must have had best-corrected visual acuity (BCVA), using ETDRS charts, of 25 letters (Snellen equivalent, 20/320) to 85 letters (Snellen equivalent, 20/20).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, patients were not excluded based on fluid levels or CST-based criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Single intravitreal administration after standard-of-care anti-VEGF
Dose cohorts as treated
“Patients were assigned to 1 of 4 cohorts based on their received dose: 440 μg cohort (1 insert; n = 3), 1030 μg cohort (1 insert; n = 1), 2060 μg cohort (2 inserts; n = 8), 3090 μg cohort (3 inserts; n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Injector deviation in the high-dose cohort
“Investigators experienced difficulties with the injector related to the advancement of the plunger as it pushed the 3 inserts (1030 μg each) through the needle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The injector issues that caused the deviation have been resolved in the subsequent phase II DAVIO 2 trial, and the device continues to be in development.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using ocular and nonocular treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcomes
| Role | Quoted record |
|---|---|
| Primary outcome | “Incidence of ocular (study eye) and systemic treatment emergent adverse events (TEAEs)” |
| Secondary outcome | “Change in best corrected visual acuity (BCVA) by EDTRS” |
| Secondary outcome | “Mean change in central subfield thickness (CST)” |
Maintenance of BCVA and CST as the targeted efficacy signal
“For this reason, patients who were already stable on anti-VEGF therapy were recruited for the DAVIO Trial. As a result, instead of the rapid improvement seen with typical anti-VEGF clinical trials in a treatment-naive population, the maintenance of stable BCVA and CST was targeted and observed in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Definition of treatment burden
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size
“No formal sample size calculations were performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All 17 patients were included in the safety analyses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, all secondary and exploratory analyses included only the 16 patients who completed the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Descriptive analyses and exclusion of one participant
“All safety, tolerability, and secondary and exploratory parameters were reported using descriptive summary statistics. No inferential statistical analysis was planned.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because no additional data were collected after week 16, the study sponsor decided to exclude this patient from the secondary and exploratory analyses to avoid the potential to skew the data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Normalization of pre-enrollment treatment burden
“Patients who were treated for <12 months prior to study enrollment had their 12-month treatment burden normalized based on the number of injections they received and the time period during which they received those injections” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Minimal-fluid subgroup definition
“A subgroup of patients from the mid- and high-dose cohorts with minimal or no fluid at baseline, defined as CST values of ≤350 μm at screening (n = 9; CST, 205–298 μm) and minimal intraretinal or subretinal fluid reported in the study eye, was identified and analyzed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Withdrawal and death of one participant
“One patient withdrew from the study after the week 16 visit due to personal concerns related to traveling during the ongoing coronavirus disease 2019 pandemic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cause of death was listed as diverticulitis, which was a preexisting condition reported in the patient’s previous medical history prior to the start of the study that had resolved and was not being treated at the time of screening per the patient’s own report.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Baseline characteristics: all 17 participants
| Characteristic | Single-dose EYP-1901, 17 participants |
|---|---|
| Age, mean (range), years | “77.4 (67–94)”View highlighted excerpt for this quote |
| Female, n (%) | “13 (76)”View highlighted excerpt for this quote |
| BCVA, ETDRS letters, mean (range) | “69 (38–85)”View highlighted excerpt for this quote |
| CST, µm, mean (range) | “299 (204–441)”View highlighted excerpt for this quote |
| Time from diagnosis to enrollment, months, median (range) | “17 (4–74)”View highlighted excerpt for this quote |
| Anti-VEGF injections in the prior 12 months, normalized, mean (range) | “8.6 (3–10)”View highlighted excerpt for this quote |
Efficacy results
Summary: DAVIO biologic activity
In DAVIO, 17 participants with previously treated wet age-related macular degeneration received a single EYP-1901 injection at 440 to 3090 μg, and 16 were included in efficacy analyses. Mean BCVA change from baseline was -1.8 letters at 6 months and -5.4 letters at 12 months, and mean CST change was +1.7 μm and +2.4 μm. At 12 months, 6 of 16 participants (37.5%) had lost 5 or more letters. Treatment burden, compared with a normalized pre-enrollment count, was reduced by 74% at 6 months and 71% at 12 months. Of 16 study eyes, 13 (81%), 8 (50%), and 5 (31%) required no additional anti-VEGF injection up to 3, 6, and 12 months, respectively. The study had no control arm, was open label, and was not powered for efficacy.
BCVA change from baseline
“A mean (range) BCVA change from baseline of +0.7 (−11 to +12), −5.2 (−51 to +10), −1.8 (−38 to +8), and −5.4 (−45 to +10) ETDRS letters was observed at 4, 5, 6, and 12 months, respectively, following administration of EYP-1901” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 16 patients who completed the study, 6 (37.5%) had a loss of ≥5 letters from baseline in BCVA at 12 months, and 10 patients (62.5%) had a loss of <5 letters, no change, or a gain from baseline in BCVA at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
CST change from baseline
“A mean (range) CST change from baseline of +2.7 (−147 to +173), +60.5 (−91 to +227), +1.7 μm (−174 to +263), and +2.4 μm (−215 to +239) was observed at 4, 5, 6, and 12 months, respectively, following administration of EYP-1901” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment burden and injection-free rates
“When comparing the number of anti-VEGF injections before and after treatment with EYP-1901, the treatment burden was reduced by 74% at 6 months and 71% at 12 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to first additional anti-VEGF treatment was 6.5 months. Thirteen eyes of 16 (81%) remained additional-injection free up to 3 months, 8 of 16 (50%) up to 6 months, and 5 of 16 (31%) up to 12 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subgroup: minimal or no fluid at screening
“In the subgroup of 9 eyes that had minimal or no fluid at screening, the mean change in BCVA from baseline was −0.4 letters (range, −12 to +8) at 6 months and −2.2 letters (range, −17 to +10) at 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixty-seven percent did not require an additional injection up to 6 months and 56% up to 12 months. The median time to first additional anti-VEGF treatment among these eyes was 12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Earlier company-reported 12-month treatment burden
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Summary of ocular TEAEs by dose
Ocular safety
“No dose-limiting toxicity was observed in this study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No patients experienced an ocular SAE or TEAE leading to discontinuation or death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no vitreous floaters, endophthalmitis, retinal detachment, insert migration into the anterior chamber, retinal vasculitis, posterior or anterior segment inflammation, vascular occlusive events, or ischemic optic neuropathy observed throughout the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient with reduced BCVA had 3 separate reductions of 17, 18, and 16 letters, and another had a single drop of 25 letters.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic safety
“Forty systemic, nonocular AEs were reported among 14 patients (82.4%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One nonocular TEAE, an increased laboratory value of γ-glutamyltransferase arising on day 58, was considered possibly treatment-related and mild.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two patients (11.8%) had SAEs during the study, including pneumonia in 1 patient and diverticulitis in the other, the latter resulting in death. In both patients, these SAEs occurred >6 months after receiving EYP-1901 at a time point when the study drug was undetectable in plasma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
DAVIO enrolled 17 participants across 4 dose cohorts (1 to 8 participants per cohort) at 11 sites in the United States, without a control arm or masking, and no formal sample size calculation was performed. Four participants in the planned 3090-μg cohort received fewer inserts than planned because of injector difficulties and were reassigned to lower-dose cohorts. Efficacy and treatment-burden analyses were descriptive, excluded 1 participant who withdrew after week 16, and were added post hoc, with pre-enrollment treatment burden normalized from historical records. The authors state that unmasked investigators may have been biased in deciding on supplemental injections. The eligibility criteria (3 or more prior injections of the same agent in 6 months, dosing 7 to 10 days after the last anti-VEGF injection) limit applicability to treatment-naive participants, and the doses tested differ from the 2.7-mg phase 3 dose. The publication was sponsored by EyePoint, and 2 authors were EyePoint employees.
Limitations stated by the authors
“Additionally, the study lacked a control group, meaning there was no comparison of the study drug with an existing therapy. Investigators were not masked to study enrollment, which may have biased their decision to administer supplemental injections during the study period. The study was not powered to make statistical comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
APEX
Objective
Study purpose: oral vorolanib (X-82) with as-needed anti-VEGF injections
“The safety and efficacy of X-82, an orally administered inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor, was investigated for treatment of wet age-related macular degeneration (AMD) in a phase II clinical trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Sites and registry dates
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-03-16” |
| Primary completion (actual) | “2017-12-12” |
Study design
Randomized, placebo-controlled dose-finding design
“This phase II, randomised, double-masked, placebo-controlled trial enrolled subjects with a prior diagnosis of exudative AMD having received at least two intravitreal injections of anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At each 4-week interval visit for 52 weeks, subjects were to be assessed to determine if rescue treatment was needed with anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Early termination
Interim analyses and the Data Safety Monitoring Committee recommendation to terminate
“Based on a planned, unbiased, interim analysis conducted, once 90% of all subjects had reached their week 36 visit, it was concluded that the study had already achieved its primary endpoint of demonstrating non-inferiority in visual acuity of those on X-82 when compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, due to the relatively frequent occurrence of liver enzyme elevations, about 20% of the patients treated with X-82, and the number of patients discontinuing therapy due to AEs, ranging from 20% to 36% in the X-82 treated patients, the Data Safety Monitoring Committee recommended to the sponsor to terminate the trial due to an insufficient benefit to risk profile.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The sponsor agreed with the recommendations, and all patients were subsequently discontinued from the study. A total of 28 (37%) of enrolled subjects were discontinued due to study termination.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Masking, trial duration, and monthly assessments
“Participants, physicians and care providers were all blinded to treatment arms.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The duration of the trial was planned for 56 weeks with 52 weeks of treatment followed by 1 month off treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At each monthly visit, ETDRS BCVA assessment, ophthalmic examination, SD-OCT imaging, laboratory assessment, urinalysis, vital signs and an ECG were completed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Eligible patients showing a response to intravitreal anti-VEGF therapy and fulfilling all other study criteria returned on Day 1 to be randomised to a study treatment group and to receive another intravitreal anti-VEGF treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Prior treatment requirement and key exclusion criteria
“Prior to enrolment, subjects were required to have received injections at intervals of 8 weeks or less and to have consistent macular fluid that was responsive to anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“pars plana vitrectomy within 30 days, the presence of proliferative diabetic retinopathy, prior glaucoma surgery and/or any other underlying diseases potentially limiting best-corrected visual acuity (BCVA) were excluded” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“a history of a cerebral vascular accident, transient ischemic attack, significant cardiac disease or evidence of active gastrointestinal disease were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Permitted as-needed anti-VEGF agents and duration of oral dosing
“Daily dosing was continued for 52 weeks followed by a 4-week observation period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Bevacizumab, ranibizumab and aflibercept were all allowed, based on investigator preference, but the drug had to remain unchanged from what the patient received prior to study enrolment and the drug remained the same for the duration of the trial.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These agents remained unchanged to eliminate the potential for any unwanted effect in our study results that could be attributed to a switch in an anti-VEGF agent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Criteria for as-needed anti-VEGF retreatment
“Patients received anti-VEGF therapy at the screening visit and returned within 14 days to document an adequate anatomic response to anti-VEGF therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“As-needed treatment with anti-VEGF was permitted if there was any increase in macular fluid/thickness compared with SD-OCT at screening visit 2 or if there was new or increased macular hemorrhage secondary to nAMD.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using visual acuity noninferiority to placebo as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized and analyzed participants
Intention-to-treat and per-protocol participants with week 52 data
“Overall, the ITT population started with a mean visual acuity of 71.0 (n=157; Snellen 20/40) and ended with a mean of 72.3 (n=81; Snellen 20/40) at week 52.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the PP population started with a mean ETDRS BCVA score of 71.7 letters (n=92; Snellen 20/40) and ended with a mean of 71.2 letters (n=68; Snellen 20/40) at week 52.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Intention-to-treat and per-protocol analysis sets and major protocol deviations
“The ITT analysis included every patient that was randomised into the clinical trial. The PP population consisted of all ITT subjects without any major violation deviation of the protocol.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The analyses of primary and secondary efficacy outcomes were performed on the PP population as a sensitivity analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of those involved in ITT population analysis, 65% (102/157) were able to avoid major protocol deviations in dosing (defined as missing ≥15% of planned X-82 doses for the entire study)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Reasons for premature discontinuation of study treatment
“Seventy-five (47.8%) subjects had study treatment prematurely discontinued for the following reasons: study termination (28 (37.3%) subjects), AE (27 (36.0%) subjects), withdrawal of consent (8 (10.7%) subjects), ‘other’ (5 (6.7%) subjects), SAEs (4 (5.3%) subjects), protocol deviation (1 (1.3%) subject), death (1 (1.3%) subject) and investigator decision (1 (1.3%) subject).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Efficacy results
Primary endpoint and anti-VEGF injection counts
“The primary endpoint of non-inferiority of visual acuity compared with placebo was demonstrated in all groups receiving X-82 (p<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a dose-dependent trend in the number of injections over a 52-week period, with the 50 mg (n=40), 100 mg (n=39), 200 mg (n=39) and placebo (n=39) group requiring 6.7, 6.0, 4.7 and 8.1 injections, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Registry primary outcome: completers at week 52
| Group | Participants analyzed | Mean (SD) change in visual acuity, letters |
|---|---|---|
| X-82 50 mg | “23” | “0.2(4.14)” |
| X-82 100 mg | “19” | “-0.9(6.57)” |
| X-82 200 mg | “17” | “1.7(5.58)” |
| Placebo | “22” | “-0.3(10.63)” |
Noninferiority estimates by dose and proportion losing fewer than 15 letters
“demonstrated a non-inferiority of visual acuity at the week 52 visit in all groups receiving X-82 when compared with placebo (−4.02 letters in the 50 mg group (p<0.000001), −1.71 letters in the 100 mg group (p<0.000001) and −2.33 letters in the 200 mg group (p<0.000001)).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The negative estimates indicate less loss (or better maintenance) of visual acuity compared with placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Those in the 50 mg, 100 mg, 200 mg and placebo groups had a mean change from baseline in visual acuity of −0.4, −0.9, 0.3 and −0.5 letters at Week 52, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 95.6% (87/91) of all patients lost fewer than 15 ETDRS letters by week 52.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Participants requiring no further anti-VEGF injection and median time to first injection
“Interestingly, there were several instances in which patients did not require another anti-VEGF injection after the final screening treatment was completed.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This was more common in those receiving X-82 (7.5% (3/40), 10.3% (4/39) and 20.5% (8/39) in the 50 mg, 100 mg and 200 mg groups, respectively) than those receiving placebo (2.6% (1/39)) but was not statistically analysed and also does not take into account follow-up time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to first anti-VEGF injection was 4.3 weeks for placebo-treated patients and 7.9, 8.1 and 8.4 weeks for patients administered 50 mg, 100 mg or 200 mg of X-82, respectively” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Per-protocol anti-VEGF injection counts by dose
“In the per-protocol group, an average of 6.3 injections were required per year.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Looking at the individual groups, there was a dose-dependent trend to less as-needed anti-VEGF injections in patients receiving X-82 compared with sham: 6.4 injections in the 50-mg group, 5.1 injections in the 100-mg group, 4.8 injections in the 200-mg group, and 8.1 injections in the sham group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Subretinal fluid on optical coherence tomography at screening and week 52
“In the placebo group, 56.4% (22/39) of patients were noted to have subretinal fluid on SD-OCT during the screening visit 2, while 81.8% (18/22) had presence of subretinal fluid at 52 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast, at the screening visit 2, 60% (24/40) of the 50 mg group, 51.3% (20/39) of the 100 mg group and 56.4% (22/39) of the 200 mg group had subretinal fluid on SD-OCT, while 78.3% (18/23), 52.6% (10/19) and 41.2% (7/17) of the 50 mg, 100 mg and 200 mg groups, respectively, had subretinal fluid on imaging on the week 52 follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Fellow eye conversion to exudative AMD by 52 weeks
“In the placebo group, 12.5% (3/24) of subjects with unilateral disease at baseline developed exudative AMD in their fellow eyes by 52 weeks, compared with 3.8% (1/26), 0% (0/27) and 0% (0/23) in the 50 mg, 100 mg, and 200 mg X-82 groups, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Selected adverse events with oral X-82
| Event | X-82 50 mg | X-82 100 mg | X-82 200 mg | Placebo |
|---|---|---|---|---|
| Serious adverse events, total | “6/40 (15.00%)” | “7/39 (17.95%)” | “3/39 (7.69%)” | “2/39 (5.13%)” |
| Alanine aminotransferase increased | “8/40 (20.00%)” | “11/39 (28.21%)” | “9/39 (23.08%)” | “2/39 (5.13%)” |
| Diarrhoea | “1/40 (2.50%)” | “4/39 (10.26%)” | “9/39 (23.08%)” | “2/39 (5.13%)” |
| Dysgeusia | “3/40 (7.50%)” | “5/39 (12.82%)” | “10/39 (25.64%)” | “0/39 (0.00%)” |
| Hair color change | “2/40 (5.00%)” | “10/39 (25.64%)” | “13/39 (33.33%)” | “0/39 (0.00%)” |
Discontinuation of oral vorolanib development in AMD
“The APEX Trial was stopped prematurely due to gastrointestinal and hepatobiliary AEs associated with oral vorolanib use such as elevated liver enzymes, and due to the fulfillment of the primary endpoint (noninferiority to placebo).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“EYP-1901 was developed as a localized, intravitreal, sustained-delivery formulation of vorolanib in an attempt to reduce the injection burden of wAMD treatment and also reduce systemic adverse effects of vorolanib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse events, severity, discontinuations, and death
“Overall, 148 (94.3%) subjects experienced at least one treatment-emergent adverse event (TEAE) and 74 (47.1%) subjects experienced one treatment-related TEAE.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 16 (10.2%) subjects overall experienced at least one severe TEAE, with 4 (2.5%) of these subjects having a TEAE that was considered related to study treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 39 (24.8%) subjects experienced at least one TEAE leading to permanent discontinuation of study treatment (8 (20.0%), 12 (30.8%), 15 (38.5%) and 4 (10.3%) subjects in the 50 mg, 100 mg, 200 mg and placebo groups, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“One (2.6%) subject died during the study (sudden cardiac death) during treatment with X-82 (100 mg), which was not considered related to study treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Early termination for sustained hepatic abnormalities by dose
“In several instances, these elevations resolved without any intervention; however, 5.0% (2/40), 15.4% (6/39) and 17.9% (7/39) in the 50 mg, 100 mg and 200 mg groups, respectively, required early termination of the trial secondary to sustained hepatic abnormalities.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No patients from the placebo group required early termination for liver enzyme elevations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
APEX evaluated daily oral vorolanib (X-82) at 50, 100, and 200 mg, not the intravitreal insert, so its efficacy results do not transfer directly to EYP-1901; its relevance to this report is the systemic adverse event profile of vorolanib at oral exposures. The trial randomized 157 participants and was stopped early after a second interim analysis, with 103 of 157 participants (65.6%) completing the study. The registry primary outcome analysis was restricted to participants who completed 52 weeks of treatment. The comparator was placebo plus as-needed anti-VEGF injections rather than a fixed-interval anti-VEGF regimen. Statements here are drawn from the full publication and the registry record.
X82-OPH-102
Objective
Location and study date
Study design
Dose escalation rules, dose-limiting toxicity definition, and maximum tolerated dose
“The dose escalated from one level to the next in the absence of any DLT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Dose-limiting toxicity was defined as a drug-related safety event during the first 2 weeks of treatment that was severe enough to require removal of the participant from the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The maximum tolerated dose was the maximum dose at which no DLT occurred in a group of 3 participants or no more than 1 DLT in a group of 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants attended for screening, day 14, and then monthly for 7 months (210 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria
Treatment
Oral X-82 dose cohorts
“Participants received oral X-82 for 24 weeks at 50 mg alternate days (n = 3), 50 mg daily (n = 8), 100 mg alternate days (n = 4), 100 mg daily (n = 10), 200 mg daily (n = 7), and 300 mg daily (n = 3), with intravitreous anti-VEGF therapy using predefined retreatment criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Criteria for anti-VEGF rescue therapy and choice of agent
“Rescue anti-VEGF therapy was permitted if predefined criteria were met, including any increase in macular fluid or thickness on SD-OCT compared to baseline, new or increased SRF or IRF, enlargement or new PED, or new or worsening macular hemorrhage.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Rescue agents were matched to each patient’s prior treatment regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled and completing participants
“Thirty-five participants with neovascular age-related macular degeneration, 7 of whom were treatment naive.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 25 participants (71%) who completed the 24 weeks of X-82 treatment, all except 1 maintained or improved their visual acuity (mean [SD], +3.8 [9.6] letters).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Efficacy analysis restricted to completers
Statistical approach and efficacy population
“No formal hypothesis testing was performed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy population comprised all those who completed the course of X-82 treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Withdrawals
“Ten participants withdrew consent or discontinued prematurely, 6 owing to adverse events attributed to X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and nausea/anorexia (n = 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Completion at 3 and 6 months and discontinuations by dose group
“Twenty-eight participants completed 3 months, and 25 completed 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 35 participants, 25 completed 24 weeks of treatment. Six discontinued X-82 owing to AEs potentially related to X-82 (2 in the 50 mg daily group, 1 each in the 100 mg daily and 200 mg groups, and 2 in the 300 mg group). Four discontinued owing to unrelated events” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Efficacy results
Visual acuity, retinal thickness, and anti-VEGF injections among completers
“Fifteen participants (60%) required no anti-VEGF injections (mean, 0.68).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean [SD] central subfield thickness reduced by −50 [97] μm, with 8 participants (all receiving at least 100 mg daily) demonstrating sustained reductions despite no anti-VEGF injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-VEGF rescue injections among completers and pre-enrollment injection rate
“The mean number of anti-VEGF injections in the 25 participants who completed 24 weeks of treatment was 0.68 (median, 0; range, 0-4; interquartile range, 0-1), with 15 (60%) not requiring any anti-VEGF rescue injections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean time to the first rescue injection was 130 days in the 10 participants who completed the study and required an injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of those assigned to 300 mg daily required intravitreous injections while receiving X-82.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Previously treated participants who completed 24 weeks of X-82 treatment had a mean (SD) of 9.0 (4.1) injections yearly prior to enrollment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Visual acuity change across all participants and by dosing frequency
“Mean BCVA change across all 35 patients was +3.5 (9.7) letters.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A gain of +4.3 (9.2) letters was seen in the 28 patients who were dosed at least daily.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In 3 patients (8.6%) dosed with 100 mg on alternate days, 200 mg daily, and 300 mg daily, an at least 5-letter worsening was seen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Central subfield thickness response at higher doses and fellow eye outcomes
“Five of 7 participants receiving 200 mg had a reduction in thickness, as did 2 of 3 receiving 300 mg.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No participants developed new neovascular AMD in the fellow eye, but 1 (receiving 50 mg daily) developed new exudation from a previously treated fellow eye CNV.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events attributed to oral X-82
“The most common adverse events attributed to X-82 were diarrhea (n = 6), nausea (n = 5), fatigue (n = 5), and transaminase elevation (n = 4). A dose relationship to the transaminase elevations was not identified; all normalized when X-82 was discontinued.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“X-82 can be associated with reversible, elevated liver enzymes; hence, liver function testing is needed to identify those unsuited to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registry adverse event totals
| Category | All participants |
|---|---|
| Serious adverse events | “3/35 (8.57%)” |
| Other adverse events | “28/35 (80.00%)” |
| Diarrhoea | “5/35 (14.29%)” |
Ocular adverse events, severe events, and serious adverse events
“There were 4 ocular AEs in 4 of 35 participants (11.4%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Three AEs (8.6%) were considered severe: 1 case of multiple myeloma, 1 of pulmonary hypertension, and 1 with an isolated, 5-fold increase in serum transaminase, which was reversible and not associated with other abnormalities (hence, not considered an SAE).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 94 systemic AEs, 32 were considered related to X-82” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Incidence of liver enzyme elevation and gastrointestinal symptoms
“Liver enzyme elevations were reported as AEs 10 times across 5 participants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The main downside of treatment was elevated liver enzymes and gastrointestinal symptoms, which occurred in 11% and 14% of participants, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 35 participants, 6 (17%) did not tolerate X-82, and an additional 4 failed to complete the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
X82-OPH-102 evaluated oral vorolanib (X-82), not the intravitreal insert, in 35 participants across 6 dose cohorts of 3 to 10 participants, without a control arm or masking. Efficacy outcomes were reported only for the 25 participants (71%) who completed 24 weeks, and 6 participants (17%) discontinued because of adverse events attributed to X-82, so the efficacy estimates are subject to attrition bias. Its relevance to this report is the systemic adverse event profile of vorolanib at oral exposures, including transaminase elevations. The study was funded by Tyrogenex, and 3 authors were Tyrogenex employees.
Author-stated limitations
“The main weaknesses, inherent to most open-label phase 1 studies, are a small sample size and lack of both masking and a control group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This study cannot determine the level of patient compliance with X-82 in a clinical setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because 80% of the participants were already receiving anti-VEGF therapy at enrollment, this may reduce the potential for clinical improvement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote